Clinical Trial Search

Primary: Intensity of Injection Site Pain — 8.3; 5.7 Score on a scale — p=0.0395

Primary: Number of Participants With Non Progression at 4 Months — 3 Participants

Primary: Difference in 6-Minute Walk Distance Between Groups (Control Minus IGF-1) for Change at 6 Months Versus Baseline — 3.4; -5.1 meters — p=0.53

Primary: Overall Survival — 4.1; 6.6 months — p=0.07

Primary: Percentage of Participants With Adverse Events — 100; 95.7 Percentage of participants

Primary: Overall Survival — 7.23; 6.21 month — p=0.032

Primary: Total Spinal Cord Independence Measure, Version III (SCIM III) Score Following Treatment With SUN13837 Injection or Placebo in Adult With Acute Spinal Cord Injury…

Primary: Percent Change in Body Weight From Baseline to Day 59 — -1.40; -3.98 Percent change in body weight — p=0.011

Primary: Change From Baseline to Week 6 in the Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS) — -8.8; -7.3; -9.1 Score on scale — p=0.89

Primary: Number of Subjects Who Received a Single Treatment of the Assigned Test Article That Were Designated as "Treatment Success" — 23; 26; 22 Participants — p=0.6084

Primary: Effect of Lanreotide on Gastrointestinal Motility as Measured by Smart Pill — 371.52; 392; 4767; 5159 minutes — p=0.07

Primary: Number of Patients That Reach a Score Equal or Lower Than 2 Ten Minutes After the Infusion of Dexmedetomidine (Assessed With the PSSS Pediatric Sedation State Scale)…

Primary: Number of Patients With Improved Disease Control — 0; 0; 0; 0 Participants

Primary: Number of Participants With Adverse Events and Serious Adverse Events — 25; 21; 4; 2 Participants

Primary: Safety: Total Body Water — 45.78; 44.17 Ohms — p=0.024